| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | SB590885 | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.026 | 0.6 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | 0.04 | 0.6 |
| mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | 0.039 | 0.6 |
| mRNA | GDC-0941 | FIMM | pan-cancer | AAC | -0.1 | 0.6 |